Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
affirmative, agent, aimed, altogether, Antitrust, bioavailablity, Bipartisan, Boulevard, carcinogenicity, Children, clarify, clarifying, clearance, climate, CMS, Congressional, curb, diversify, divestiture, DRL, expiry, feet, fierce, Francisco, function, globally, House, HSR, Informatica, Landlord, lifecycle, lifespan, LLC, longer, Mateo, metric, moiety, multinational, predefined, Reddy, Redwood, relocate, rent, San, Seaport, simplification, sNDA, square, Sunshine, TherapeuticEquivalence, transparency, turnover, UK, unsure
Removed:
AbbVie, acetate, acitretin, adalimumab, adjunctive, AG, alemtuzumab, allocated, allocating, Amgen, anthrolin, approximated, apremilast, arriving, assessed, asset, assistance, assumed, attributable, AUBAGIO, AVONEX, AZILECT, Bayer, begun, Benckiser, beta, BETASERON, BioPharma, borrowing, Bristol, brodalumab, capsule, Celgene, cloud, computing, content, contra, COPAXONE, COSENTYX, cyclosporine, DAC, daclizumab, deliverable, deter, determining, deterrent, discounted, distinct, divestment, division, DUOPA, element, Eli, ENBREL, Equivalence, etanercept, Europe, exercised, existence, EXTAVIA, facilitate, fingolimod, forma, gene, Genzyme, GILENYA, glatiramer, Goodwill, Holding, HUMIRA, HYP, Idec, identification, Impax, Imputation, incremental, infliximab, interferon, interpret, invalidity, ixekizumab, Johnson, laquinimod, LEMTRADA, lender, Lilly, listing, measure, measurement, mesylate, methotrexate, MMA, Modernization, monomethyl, mutually, natralizumab, object, ocrelizumab, operated, Osmotica, OTEZLA, peginterferon, pipeline, plc, PLEGRIDY, pro, rasagiline, reacquired, reacquisition, REBIF, Reckitt, reconstitute, REMICADE, represented, requested, reviewed, Roche, RYTARY, Sanofi, screening, sector, secukinumab, Serono, Simplifying, SINEMET, size, software, Squibb, STALEVO, STELARA, subsidiary, Sun, synthetic, teriflunomide, terminable, therapy, tildrakizumab, tofacitinib, topical, typically, TYSABRI, underwriting, underwritten, unit, unnecessary, unobservable, updated, ustekinumab, vitamin, XL
Filing tables
Filing exhibits
Related press release
XNPT similar filings
Filing view
External links